P. Berthaud
9 Papers
65 Citations
P. Berthaud is an academic researcher. The author has contributed to research in topics: GiST & Internal medicine. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
C. Delbaldo,Etienne Chatelut,Micheline Re,Alain Deroussent,Sophie Séronie-Vivien,Aurore Jambu,P. Berthaud,Axel Le Cesne,Jean-Yves Blay,Gilles Vassal +9 more
TL;DR: The plasma AAG levels influenced imatinib pharmacokinetics, with the plasma α1-acid glycoprotein (AAG) levels indicating that both clearance values decreased at a higher AAG level.
168
Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life
A. Le Cesne,David Pérol,I.L. Ray-Coquard,B. Bui,Florence Duffaud,Maria Rios,J.-M. Coindre,J.F. Emile,P. Berthaud,J.-Y. Blay +9 more
TL;DR: Primary endpoint was progression-free survival (PFS); secondary endpoints were OS, quality of life (QoL), secondary response after IM re-introduction, identification of molecular determinants of response.
34
Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial
B. Bui,A. Le Cesne,I.L. Ray-Coquard,Florence Duffaud,Maria Rios,Antoine Adenis,E. Bonpas,David Pérol,P. Berthaud,J.-Y. Blay +9 more
TL;DR: These results confirm the poor prognosis of VHR GIST pts and justify IM treatment of initially resected metastatic GIST like other metastatic diseases.
9
Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group
Nicolas Penel,A. Le Cesne,B. Bui,M. Tubiana-Hulin,C. Guillemet,Didier Cupissol,P. Berthaud,C. Mahier,David Pérol,J.-Y. Blay +9 more
TL;DR: Imatinib induces prolonged disease stabilization in the majority of evaluable patients with AF/DT in whom no local treatment option was available, and this phase II trial is reported.
8
Erythropoietin for anemia treatment of patients with GIST receiving imatinib
Florence Duffaud,A. Lecesne,I.L. Ray-Coquard,E. Bompass,K. Assi,P. Berthaud,Françoise Ducimetière,J.-Y. Blay +7 more
TL;DR: EPO increases hemoglobin level in most anaemic GIST patients who have not progressed under imatinib treatment, but not in refractory GIST Patients.
7